Boston’s biotech scene may be gearing up for another high-profile IPO moment—this time led by a company betting big on the future of depression treatment.
Seaport Therapeutics, a relatively young but well-funded player based in the city’s Seaport district, is preparing to enter public markets with a clear mission: push its pipeline of neuropsychiatric drugs into late-stage development. At the heart of the story is its lead candidate, SPT-300, a next-generation treatment for major depressive disorder that could soon advance into Phase 3 trials if the company secures fresh capital.
Unlike many early-stage biotech IPOs that lean heavily on long-term promises, Seaport’s pitch feels more immediate. The company is already running a Phase 2b study, with results expected in the near future, and is openly signaling that IPO proceeds would be used to accelerate that program—and potentially bring it across the finish line.
What makes Seaport particularly interesting for investors is its underlying technology. Its proprietary “Glyph” platform is designed to help drugs bypass the liver’s initial metabolism, improving how much of the active compound actually reaches the bloodstream. In practical terms, that could mean lower doses, fewer side effects, and more convenient oral treatments—especially significant in a space like depression, where adherence and tolerability are constant challenges.
The company’s lead drug builds on allopregnanolone, a neurosteroid already used in a different form to treat postpartum depression. Seaport’s twist is turning that mechanism into a pill rather than an IV therapy, which, if successful, could dramatically expand its use.
Beyond SPT-300, the pipeline hints at a broader ambition. Another candidate, SPT-320, targets anxiety and sleep disorders, while an earlier-stage program explores a non-hallucinogenic derivative of LSD—an area that has been quietly gaining traction across the biotech industry.
Financially, Seaport isn’t starting from zero. The company has already raised more than $300 million since its 2024 launch and entered 2026 with over $230 million still on hand. But late-stage clinical trials are notoriously expensive, and the move toward an IPO suggests leadership sees a window—however narrow—to tap public markets before conditions shift again.
That timing matters. Biotech IPO activity showed signs of life earlier this year after a sluggish stretch, though momentum has been uneven. Seaport’s debut could serve as a litmus test for whether investors are ready to back another wave of high-risk, high-reward drug development stories.
For Boston, it’s another reminder of the city’s enduring role as a biotech powerhouse—where science, capital, and ambition continue to collide, often with billions of dollars and years of research hanging in the balance.
